Intra-Cellular Therapies Stock (NASDAQ:ITCI), Analyst Ratings, Price Targets, Predictions

The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Needham on May 8, 2024. The analyst firm set a price target for $90.00 expecting ITCI to rise to within 12 months (a possible 37.28% upside). 37 analyst firms have reported ratings in the last year.

The latest analyst rating for Intra-Cellular Therapies (NASDAQ: ITCI) was provided by Needham, and Intra-Cellular Therapies reiterated their buy rating.

There is no last upgrade for Intra-Cellular Therapies.

The last downgrade for Intra-Cellular Therapies Inc happened on August 22, 2022 when Goldman Sachs changed their price target from $64 to $49 for Intra-Cellular Therapies Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intra-Cellular Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intra-Cellular Therapies was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

While ratings are subjective and will change, the latest Intra-Cellular Therapies (ITCI) rating was a reiterated with a price target of $0.00 to $90.00. The current price Intra-Cellular Therapies (ITCI) is trading at is $65.56, which is within the analyst’s predicted range.